Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Jie Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6219-8177; OpenAlex author ID A5103051807. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2014: 4 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Co-author DOI 10.1186/s12943-025-02326-6↗
  2. ZBTB7A interferes with the RPL5-P53 feedback loop and reduces endoplasmic reticulum stress-induced apoptosis of pancreatic cancer cells. Co-author DOI 10.1002/mc.23772↗
  3. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0369-0↗
  4. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC. Co-author DOI 10.18632/oncotarget.5668↗
  5. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.12.021↗
  6. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Co-author DOI 10.1186/1476-4598-13-130↗
  7. Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the … Co-author DOI 10.1186/s12967-014-0309-8↗
  8. Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into th… Co-author DOI 10.3892/or.2014.3113↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zekuan Xu · 7 shared papers, 2014–2025 · strength 0.47
  2. Kun-Ling Xie · 6 shared papers, 2014–2025 · strength 0.42
  3. Wentao Gao · 3 shared papers, 2014–2025 · strength 0.28
  4. Kuirong Jiang · 3 shared papers, 2014–2025 · strength 0.28
  5. Zheng Li · 2 shared papers, 2014–2025 · strength 0.25
  6. Yunpeng Peng · 2 shared papers, 2014–2025 · strength 0.25
  7. Zhuyin Qian · 2 shared papers, 2014–2025 · strength 0.25
  8. Junli Wu · 2 shared papers, 2014–2025 · strength 0.25
  9. Ming Xu · 1 shared paper, 2024 · strength 0.23
  10. Xiaofei Zhi · 5 shared papers, 2014–2016 · strength 0.22
  11. Jingjing Zhang · 1 shared paper, 2025 · strength 0.21
  12. Yi Miao · 1 shared paper, 2025 · strength 0.21
  13. Jingjing Zhang · 4 shared papers, 2014 · strength 0.16
  14. Linjun Wang · 2 shared papers, 2015–2016 · strength 0.10
  15. Yi Miao · 2 shared papers, 2014 · strength 0.07
  16. Jianping Zhou · 1 shared paper, 2015 · strength 0.04
  17. Zheng Li · 1 shared paper, 2014 · strength 0.04
  18. Yi Zhu · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.